The settlement resolves allegations that Thomas Whalen, DO, submitted false claims to federal health plans for FDA-approved medications when he administered medications that were not approved by the FDA.
Dr. Whalen administered the non-FDA-approved medications at Whalen Rheumatology, which had offices in Havertown and Exton, Pa. He allegedly received approximately $1.1 million in illicit gains by giving patients the non-FDA-approved medications and then billing insurers as if he had used approved medications, according to the Justice Department.
The settlement also resolves Dr. Whalen’s violations of the Controlled Substances Act. He admitted to prescribing controlled substances to two patients without a legitimate medical purpose, according to the Justice Department.
Dr. Whalen permanently surrendered his controlled substance registrations with the Drug Enforcement Administration, surrendered his medical license and will be excluded from participation in federal programs.
More articles on legal and regulatory issues:
Chicago hospital defeats allegations of ‘ghost payroll’ scheme
West Virginia hospital settles whistleblower suit for $50M
UnitedHealth accused of illegally deflating reimbursement
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.